Tripokin

Tripokin is a **multi-specific immunocytokine fusion protein** in preclinical development by **Philogen** for cancer immunotherapy. It consists of the **L19 antibody** fused to **interleukin-2** and a **single amino acid mutant of tumor necrosis factor**, designed to localize selectively to tumors by binding the **extradomain B of fibronectin** in the tumor microenvironment. Once localized, the TNF moiety is intended to induce rapid hemorrhagic tumor necrosis, while the IL-2 moiety activates and expands anti-tumor immune effector cells through IL-2 receptor signaling. Preclinical reports indicate anti-tumor activity and potential synergy with immune checkpoint blockade, but the program appears to remain **preclinical / in development** with no established clinical-stage indication publicly confirmed from the provided context.

Other names

L19-IL2-TNFL-19-IL2-TNFL 19-IL2-TNF